about
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Safinamide for the treatment of Parkinson's disease.
@en
type
label
Safinamide for the treatment of Parkinson's disease.
@en
prefLabel
Safinamide for the treatment of Parkinson's disease.
@en
P2093
P2860
P1476
Safinamide for the treatment of Parkinson's disease.
@en
P2093
Meena A Kanikannan
Rupam Borgohain
Shaik Afshan Jabeen
P2860
P304
P356
10.1586/17512433.2014.968555
P407
P577
2014-10-10T00:00:00Z